Access event photos here.
About the event:
WRCB announces a one day, in - person summit on ‘Next Generation Therapeutics’. In this summit, we aim to bring experts - academics, scientists, industry leaders, clinicians, government and non-profit representatives, incubators and startups – together to share their thought leadership in the domains of Drug Discovery and Delivery and Regenerative Medicine (Cell Therapy and Tissue Medicine). The event will catalyse discussions and potential collaborations between the stakeholders.
Event convenor: Prof Abhijit Majumder, Chemical Engineering Department
Co-convenor: Prof Shamik Sen, Department of Biosciences and Bioengineering
Themes:
Drug Discovery and Delivery
Regenerative Medicine (Cell Therapy and Tissue Medicine)
Date: 18th Nov 2022, Friday
Time: 9.00am – 5.30 pm
Venue: Prof. B. Nag Auditorium, Ground floor, Victor Menezes Convention Centre (VMCC), IIT Bombay
Deadlines:
Registration: closed
Poster Abstract Submission: closed
Prominent names from the field are speaking at the event:
Dr. Shailja Vaidya Gupta
Formerly in the Office of the Principal Scientific Adviser to Government of India as a Senior Adviser
Dr. Pravin Kumar Vermula
Principal Investigator and Ramalingaswami Fellow, Institute for Stem Cell Biology and Regenerative Medicine (inStem)
Dr. Inderjeet Kaur
Scientist, Kallam Anji Reddy Molecular Genetics Laboratory, LV Prasad Eye Institute
Prof. Sourabh Ghosh
Professor, Department of Textile and Fibre Engineering, Indian Institute of Technology Delhi
Dr. Shridhar Narayanan
CEO, Foundation of Neglected Disease Research
Prof. Amitabha Bandyopadhyaya
Faculty in Charge, Bioincubator, Indian Institute of Technology, Kanpur
Dr. S Narasimha Murthy
Founder Director, Institute for Drug Delivery and Biomedical Research (IDBR)
Dr. Aman Sharma
Director and Founder, Exocan Healthcare
Dr. Amjad Husain
Senior Principal Scientist & General Manager R&D, Biocon Biologics
Dr. Vrisha Madhuri
Professor of Paediatric Orthopaedics, Christian Medical College Vellore
Mr.Anup Choudhary
Vice President & Delivery Manager Differentiated Formulations & Topicals, Dr Reddy’s Laboratories
Dr. Priti Warke
Director, Cell Biology and Head, QA & Regulatory affairs, HiMedia labs Pvt Ltd
Prof. Prakriti Tayalia
Professor, Dept of Biosciences and Bioengineering, Indian Institute of Technology Bombay
Dr. Chirayu Padhiar
Senior Medical Director, LifeCell International Pvt. Ltd.
Wadhwani Research Centre for Bioengineering (WRCB) was set up to be a world-class translational research centre in bioengineering at the Indian Institute of Technology, Bombay (IITB). WRCB supports faculty members across various departments of IITB in undertaking breakthrough interdisciplinary translational research. The projects carried out by the faculty members associated with WRCB have resulted in several patents and spin-off companies in diverse areas ranging from diagnostics to drug discovery.
Currently in its 7th year, the centre was established through a generous donation by Dr. Romesh Wadhwani - a successful serial entrepreneur and a signatory to the ‘giving pledge’. Dr. Wadhwani envisioned WRCB as a catalyst to enable India to be at the forefront of the bioengineering industry. The four core focus areas of the centre are Diagnostics, Therapeutics, MedTech, and Synthetic Biology
The projects carried out by the faculty members associated with WRCB have resulted in 70+ publications, 50+ patent applications, and 4 spinoff companies. Recent spin-offs from WRCB include ImmunoACT- a CAR-T cell therapy company, Clarity Biosystems – a company specializing in a highly accurate new-born screening platform, Metflux - using proprietary platform to accelerate physiological & therapeutic research and bring personalized digital solutions for healthcare and Algorithmic Biologics, whose technology greatly simplifies large scale pooled molecular testing which is useful in situations such as the covid pandemic and other applications that warrant large numbers of samples to be tested. In addition to these recent spin-offs, the centre has an active year-to-year commercialization pipeline.
